Eun Yang
Stock Analyst at Jefferies
(0.55)
# 3,767
Out of 4,814 analysts
46
Total ratings
33.33%
Success rate
-27.62%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $284.96 | +51.60% | 8 | Sep 23, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: Hold | $65 → $2 | $2.77 | -27.80% | 3 | Jun 17, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $1.45 | +451.72% | 2 | May 14, 2024 | |
| ATXS Astria Therapeutics | Maintains: Buy | $22 → $27 | $4.11 | +556.93% | 2 | Mar 25, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $7 → $1.5 | $0.27 | +461.17% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $33.52 | -1.55% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $1.71 | +1,537.43% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $15.98 | +68.96% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $2.00 | +250.00% | 1 | Feb 10, 2023 | |
| CVAC CureVac | Upgrades: Buy | n/a | $3.21 | - | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.39 | +1,698.56% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $75 | $0.81 | +9,210.99% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $84 | $84.22 | -0.26% | 3 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.05 | +2,280.95% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $4.78 | - | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $12.12 | +188.78% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $273.68 | -19.61% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $38 → $31 | $28.95 | +7.08% | 5 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $116.58 | +165.91% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $104.33 | -23.32% | 3 | Jul 11, 2017 |
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $284.96
Upside: +51.60%
Aerovate Therapeutics
Jun 17, 2024
Downgrades: Hold
Price Target: $65 → $2
Current: $2.77
Upside: -27.80%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $1.45
Upside: +451.72%
Astria Therapeutics
Mar 25, 2024
Maintains: Buy
Price Target: $22 → $27
Current: $4.11
Upside: +556.93%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $7 → $1.5
Current: $0.27
Upside: +461.17%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $33.52
Upside: -1.55%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $1.71
Upside: +1,537.43%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $15.98
Upside: +68.96%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $2.00
Upside: +250.00%
CureVac
Jan 9, 2023
Upgrades: Buy
Price Target: n/a
Current: $3.21
Upside: -
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $1.39
Upside: +1,698.56%
Sep 22, 2022
Maintains: Buy
Price Target: $525 → $75
Current: $0.81
Upside: +9,210.99%
Aug 22, 2022
Maintains: Buy
Price Target: $78 → $84
Current: $84.22
Upside: -0.26%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $1.05
Upside: +2,280.95%
Jul 12, 2021
Initiates: Buy
Price Target: n/a
Current: $4.78
Upside: -
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $12.12
Upside: +188.78%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $273.68
Upside: -19.61%
Nov 3, 2017
Maintains: Hold
Price Target: $38 → $31
Current: $28.95
Upside: +7.08%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $116.58
Upside: +165.91%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $104.33
Upside: -23.32%